Search

Evaluation of a phased pneumococcal conjugate vaccine introduction in Mongolia using enhanced pneumonia surveillance and community carriage surveys

Streptococcus pneumoniae causes substantial morbidity and mortality among children. The introduction of pneumococcal conjugate vaccines (PCV) has the potential to dramatically reduce disease burden. As with any vaccine, it is important to evaluate PCV impact, to help guide decision-making and resource-allocation.

Describing skin health and disease in urban-living Aboriginal children: co-design, development and feasibility testing of the Koolungar Moorditj Healthy Skin pilot project

Indigenous children in colonised nations experience high rates of health disparities linked to historical trauma resulting from displacement and dispossession, as well as ongoing systemic racism. Skin infections and their complications are one such health inequity, with the highest global burden described in remote-living Australian Aboriginal and/or Torres Strait Islander (hereafter respectfully referred to as Aboriginal) children. Yet despite increasing urbanisation, little is known about the skin infection burden for urban-living Aboriginal children.

Transmission potential of Streptococcus pyogenes during a controlled human infection trial of pharyngitis

Controlled human infection (CHI) models can provide insights into transmission of pathogens such as Streptococcus pyogenes (Strep A). As part of the Controlled Human Infection with Penicillin for Streptococcus pyogenes (CHIPS) trial, we explored the potential for transmission among participants deliberately infected with the Strep A emm75 strain.

Host-dependent resistance of Group A Streptococcus to sulfamethoxazole mediated by a horizontally-acquired reduced folate transporter

Described antimicrobial resistance mechanisms enable bacteria to avoid the direct effects of antibiotics and can be monitored by in vitro susceptibility testing and genetic methods. Here we describe a mechanism of sulfamethoxazole resistance that requires a host metabolite for activity.

Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow fibre model and mathematical modelling

Acute rheumatic fever (ARF), an autoimmune reaction to Group A Streptococcus (Streptococcus pyogenes; Strep A) infection, can cause rheumatic heart disease (RHD). New formulations of long-acting penicillins are being developed for secondary prophylaxis of ARF and RHD.

Acute Rheumatic Fever Diagnosis Collaborative Network (ARC)

ARC is a global network of collaborators committed to reducing the burden of RHD in our lifetime.

Defining target penicillin concentrations for subsequent studies of a reformulated long-acting benzathine penicillin prototype

Aims: To determine the minimum inhibitory concentrations of penicillin G against a representative collection of Strep A strains; and to evaluate the impact of penicillin G concentration and size of bacterial inoculum on the prophylactic effect for Strep A strains

START: Towards a diagnostic test for rheumatic fever

In this study we will use new methods to comprehensively test immune responses in blood samples from people with ARF (diagnosed using the Jones Criteria) and healthy volunteers at Royal Darwin and from Auckland Hospital, New Zealand, to find any unique signature that reliably identifies ARF.

STopping Acute Rheumatic Fever Infections to Strengthen Health (STARFISH)

STopping Acute Rheumatic Fever Infections to Strengthen Health (STARFISH) brings together a diverse and multidisciplinary research team to investigate the most effective environmental health initiatives (EHIs) aimed at reducing Strep A infections and prevent Acute Rheumatic Fever (ARF).

Genetic Manipulation of Group A Streptococcus-Gene Deletion by Allelic Replacement

An optimized, rapid method for creating markerless isogenic mutations that combines Gibson assembly cloning with a new temperature-sensitive plasmid, pLZts